Jason Springer, MD, MS, served as one of the lead authors of the ACR/VF guidelines for polyarteritis nodosa (PAN), and talks about the recommendations specific to PAN here.... [Read More]
Vasculitis Guidelines in Focus, Part 4: Polyarteritis Nodosa
Search results for: cancer
Summer 2021’s Awards, Appointments & Announcements in Rheumatology
Marian Hannan Celebrated after 10 Years as AC&R Editor-in-Chief By Kelly April Tyrrell This summer, the 10-year tenure of Marian Hannan, MPH, DSc, as editor in chief of Arthritis Care & Research (AC&R), has come to an end. Kelli Allen, PhD, assumed the post on July 1. “Marian has done a fantastic job over the… [Read More]
COVID-19 Vaccination Induces T Cell Response in Patients Treated with Rituximab
Research indicates mRNA vaccination for SARS‐CoV‐2 infection may induce a T cell response in vulnerable, immunocompromised patient populations being treated with rituximab.... [Read More]
In Memoriam: Ronald Olejko—May 4, 1950–Sept. 5, 2021
Ronald Frank Olejko (71)—who many ACR/ARP members knew as the man who managed the smooth planning and execution of the ACR’s annual meeting for more than 40 years—passed away on Sunday, Sept. 5, after a long battle with bladder and kidney cancer. He died peacefully at home with friends and loved ones by his side…. [Read More]
FDA Requires New Boxed Warnings on JAK Inhibitors, Places Restrictions on Use
On Sept. 1, the U.S. Food & Drug Administration (FDA) announced that it is requiring revisions to the Boxed Warning for the Janus kinase (JAK) inhibitors Xeljanz/Xeljanz XR (tofacitinib), Olumiant (baricitinib) and Rinvoq (upadacitinib) to include information about the risks of serious heart-related events, cancer, blood clots and death.1 Recommendations for healthcare professionals will include… [Read More]
AbbVie, Lilly Face New Delays in FDA Approval for Expanded Use of Janus Kinase Inhibitors
(Reuters)—AbbVie Inc. and ELi Lilly & Co. are facing fresh delays in the approval of their respective rheumatoid arthritis (RA) drugs for treating the chronic skin disease eczema as the U.S. health regulator assesses the new class of treatment over safety concerns. The treatment, called Janus kinase inhibitors (jakinibs), blocks inflammation-causing enzymes known as Janus… [Read More]
CDC Advisers Consider Boosters for Immune-Compromised Americans
CHICAGO (Reuters)—Advisers to the U.S. Centers for Disease Control & Prevention will consider evidence suggesting that a booster dose of COVID-19 vaccines could increase protection among people with compromised immune systems. Data presented ahead of the July 22 meeting noted that people with compromised immune systems have a reduced antibody response following the recommended primary… [Read More]
Webside Care Can Enhance Rheumatology Training & Patient Satisfaction
Many practitioners can relate to the epiphany of Roy Basch, MD, the lead character in Samuel Shem’s satirical novel The House of God.1 During his first on-call shift as a medicine intern, long work hours combined with jaded advice from his senior resident leave Dr. Basch feeling disenchanted with the medical profession until he cares… [Read More]
Researchers Explore Response to COVID-19 Vaccines in the Elderly
A delayed second dose of an mRNA vaccine may provide better protection against COVID-19 in elderly patients.... [Read More]
High Cost of Specialty Drugs Demands Action
Amid rising drug costs and the growing influence of pharmacy benefit managers on patient care decisions, physicians are increasingly called upon to advocate for affordable, evidence-based treatments for their patients.... [Read More]
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 71
- Next Page »